Status: Recruiting
Gadopiclenol vs. Gadobutrol for Dynamic Contrast-Enhanced Pituitary MRI (Magnetic Resonance Imaging)
This study will evaluate the efficacy and safety of Gadopiclenol, an FDA-approved contrast agent, for visualizing pituitary lesions on MR images by comparing with the comparator, Gadobutrol, a clinically widely used contrast agent. The study is double-blinded, so neither the participants nor the researchers know which contrast agent is being used during each scan to avoid the bias of results.
Participants needed: 10
Trial details
Phase: Phase 4Age: 19+Biological sex: AllType: InterventionalSponsor: UConn HealthUpdated: Apr 28, 2026Locations: 1
Eligibility criteria
Male adult patient who is at 18 years old or above, or female adult patient who... [+6]
Patient presenting with known class III/IV congestive heart failure according to... [+5]